Clinical practice guidelines for ovarian cancer: an update to the Korean Society of Gynecologic Oncology guidelines

1 6

Cited 0 times in

Authors: Lee, Banghyun ; Chang, Suk-Joon ; Kwon, Byung Su ; Son, Joo-Hyuk ; Lim, Myong Cheol ; Kim, Yun Hwan ; Lee, Shin-Wha ; Choi, Chel Hun ; Eoh, Kyung Jin ; Lee, Jung-Yun ; Lee, Yoo-Young ; Suh, Dong Hoon ; Kim, Yong Beom

MeSH: Carcinoma, Ovarian Epithelial* / therapy ; Female ; Gynecology / standards ; Humans ; Medical Oncology / standards ; Ovarian Neoplasms* / diagnosis ; Ovarian Neoplasms* / therapy ; Republic of Korea ; Societies, Medical

Keywords: Hyperthermic Intraperitoneal Chemotherapy ; Risk-educing Salpingo-oophorectomy ; Poly(ADP-ribose) Polymerase (PARP) Inhibitor ; Mirvetuximab Soravtansine ; Trastuzumab Deruxtecan ; Practice Guideline ; Ovarian Neoplasms

Abstract: We updated the Korean Society of Gynecologic Oncology (KSGO) practice guideline for the management of ovarian cancer as version 5.1. The ovarian cancer guideline team of the KSGO published announced the fifth version (version 5.0) of its clinical practice guidelines for the management of ovarian cancer in December 2023. Inversion 5.0, the selection of the key questions and the systematic reviews were based on the data available up to December 2022. Therefore, we updated the guidelines version 5.0 with newly accumulated clinical data and added 5 new key questions reflecting the latest insights in the field of ovarian cancer between 2023 and 2024. For each question, recommendation was provided together with corresponding level of evidence and grade ofrecommendation, all established through expert consensus.